Clinical use of biomarkers for toxicant-induced acute kidney injury
Timothy J Pianta, Nicholas A Buckley, Philip W Peake, Zoltan H Endre
BIOMARKERS IN MEDICINE | FUTURE MEDICINE LTD | Published : 2013
Toxicant-induced acute kidney injury (ToxAKI) causes substantial morbidity and retards drug development. ToxAKI is relatively underexplored compared with ischemia-reperfusion injury in clinical biomarker studies. We highlight the rationale for novel AKI biomarkers in management of ToxAKI, and review the contemporary evidence supporting their clinical use. Directly-acting nephrotoxins, such as cisplatin, aminoglycosides, vancomycin and radiocontrast, remain widely used and highlight how novel biomarkers can either improve the detection of changes in glomerular filtration rate or directly signal cellular injury and structural damage. Serum cystatin C has already improved clinical risk predicti..View full abstract
TJ Pianta gratefully acknowledges the financial support of the Jacquot Research Entry Scholarship and a University of New South Wales Australian Postgraduate Award. ZH Endre has received research and travel support from Alere and Abbott. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.